SESN2 Could Be a Potential Marker for Diagnosis and Prognosis in Glioma

Xu, Lingdan; Liu, Zelin; Lu, Jiyuan; Xu, Jia; Meng, Yucheng; Huang, Ke; Liu, Bin

doi:10.3390/genes14030701

Cited by 6 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, not enough samples are available for a separate analysis for the rare concurrence of these two diseases. Also, previous studies have analyzed different graded of glioma together when looking for prognostic factors ( 29 , 30 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and prognostic analysis of patients with HIV and glioma: A case series and literature review

Ding,

Liang,

Liang

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

Cerebral glial tumors have become increasingly common in human immunodeficiency virus (HIV)-positive patients. The present study aimed to report a series of such cases, explore their clinical and pathological characteristics and subject all the reported cases to a survival analysis. The characteristics, management and prognosis of 10 HIV-positive patients with brain gliomas enrolled in a single hospital were investigated in detail. Immunohistochemical assessment of CD31, CD68 and CD163 was performed in the 10 HIV-positive patients with glioma and 18 HIV-negative patients with glioma. The relevant literature was also reviewed using relevant search terms. The potential predictive factors were screened by univariate and multivariate logistic regression analyses, and a nomogram was established based on the potential predictive factors. A total of 50 patients, including the 10 primary cases, were included in the survival analysis. The median survival time was 9 months. The gliomas of HIV-negative patients had a lower cell count of CD163 + cells than those of HIV-positive patients. High CD4 + T-cell count and the use of highly active antiretroviral therapy (HAART) tended to increase the median survival duration, although not significantly according to the log-rank analysis. In the univariate analysis, only surgery, radiotherapy (RT) and World Health Organization (WHO) tumor grade had significant associations with overall survival. In the multivariate analysis, only RT and WHO grade were independent predictors. In conclusion, gliomas may occur more frequently in HIV-positive populations than is currently recognized. The survival duration of most HIV-positive patients with glioma is determined by the tumor rather than HIV status. Adjuvant radiotherapy and the WHO grade of the glioma are predicted to be independent prognostic factors. Surgical resection followed by RT plus regular HAART is recommended for patients with glioma who are HIV-positive.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical characteristics and prognostic analysis of patients with HIV and glioma: A case series and literature review

Ding,

Liang,

Liang

et al. 2024

Exp Ther Med

View full text Add to dashboard Cite

show abstract

SESN2 attenuates sevoflurane-induced cognitive impairment and neuroinflammation in rats

Sun,

Li,

Wang

et al. 2023

Exp Brain Res

View full text Add to dashboard Cite

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Dogra,

Singh,

Kumar

2024

Mol Neurobiol

View full text Add to dashboard Cite

Aims Glioblastoma (GBM) is the highest-grade of glioma for which no effective therapy is currently available. Despite extensive research in diagnosis and therapy there has been no signi cant improvement in GBM outcomes, with a median overall survival continuing at a dismal 15-18 months. In recent times, glioblastoma stem cells (GSCs) have been identi ed as crucial drivers of treatment resistance and tumor recurrence; and GBM therapies targeting GSCs are expected to improve patient outcomes. We used a multistep screening strategy to identify repurposed candidate drugs against therapeutic molecular targets in GBM with potential to concomitantly target GSCs. Main methods Common differentially expressed genes (DEGs) were identi ed through analysis of multiple GBM and GSC datasets from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA). For identi cation of target genes, we further selected the genes with most signi cant effect on overall patient survival. The relative mRNA and protein expression of the selected genes in TCGA control versus GBM samples was also validated and their cancer dependency scores were assessed. Drugs targeting these genes and their corresponding proteins were identi ed from LINCS database using Connectivity Map (CMap) portal, and by in silico molecular docking against each individual target using FDA approved drugs library from DrugBank database, respectively. The molecules thus obtained were further evaluated for their ability to cross blood brain barrier (BBB) and their likelihood of resulting in drug resistance by acting as p-glycoprotein (p-Gp) substrates. The effect of these nal shortlisted compounds on a panel of GBM cell lines was examined and compared with temozolomide through the drug sensitivity EC50 values and AUC from the PRISM Repurposing Secondary Screen, and IC50 values obtained from GDSC portal. Key ndings We identi ed RPA3, PSMA2, PSMC2, BLVRA and HUS1 as molecular targets in GBM including GSCs with signi cant impact on patient survival. Our results show GSK-2126458, linifanib, drospirenone, eltrombopag, nilotinib and PD198306 as candidate drugs which can be further evaluated for their anti-tumor potential against GBM. Signi cance Through this work we identi ed repurposed candidate therapeutics against GBM utilizing a GSC inclusive targeting approach, which demonstrated high in vitro e cacy. These drugs have the potential to be developed as individual or combination therapy to improve GBM outcomes.

show abstract

SESN2 Could Be a Potential Marker for Diagnosis and Prognosis in Glioma

Cited by 6 publications

References 66 publications

Clinical characteristics and prognostic analysis of patients with HIV and glioma: A case series and literature review

Clinical characteristics and prognostic analysis of patients with HIV and glioma: A case series and literature review

SESN2 attenuates sevoflurane-induced cognitive impairment and neuroinflammation in rats

A Multistep In Silico Approach Identifies Potential Glioblastoma Drug Candidates via Inclusive Molecular Targeting of Glioblastoma Stem Cells

Contact Info

Product

Resources

About